search
Back to results

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Primary Purpose

Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
anti-thymocyte globulin
cyclophosphamide
cyclosporine
fludarabine phosphate
mycophenolate mofetil
umbilical cord blood transplantation
total body irradiation
Sponsored by
Fred Hutchinson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring chronic myelogenous leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, atypical chronic myeloid leukemia, chronic myelomonocytic leukemia, anaplastic large cell lymphoma, splenic marginal zone lymphoma, nodal marginal zone B-cell lymphoma, recurrent adult Hodgkin lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent childhood large cell lymphoma, recurrent mycosis fungoides/Sezary syndrome, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, recurrent/refractory childhood Hodgkin lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, refractory multiple myeloma, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, myelodysplastic/myeloproliferative disease, childhood myelodysplastic syndromes, recurrent childhood anaplastic large cell lymphoma, refractory anemia, refractory anemia with excess blasts, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, stage III adult diffuse large cell lymphoma, stage IV adult diffuse large cell lymphoma, stage III adult immunoblastic large cell lymphoma, stage IV adult immunoblastic large cell lymphoma, stage III childhood anaplastic large cell lymphoma, stage III childhood large cell lymphoma, stage IV childhood anaplastic large cell lymphoma, stage IV childhood large cell lymphoma, stage III adult Hodgkin lymphoma, stage III childhood Hodgkin lymphoma, stage IV adult Hodgkin lymphoma, stage IV childhood Hodgkin lymphoma, stage II multiple myeloma, stage III multiple myeloma, stage III chronic lymphocytic leukemia, stage IV chronic lymphocytic leukemia, stage III small lymphocytic lymphoma, stage IV small lymphocytic lymphoma, stage III marginal zone lymphoma, stage IV marginal zone lymphoma, stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, Waldenstrom macroglobulinemia, stage III mantle cell lymphoma, stage IV mantle cell lymphoma, stage III mycosis fungoides/Sezary syndrome, stage IV mycosis fungoides/Sezary syndrome, juvenile myelomonocytic leukemia, chronic eosinophilic leukemia, chronic idiopathic myelofibrosis, chronic neutrophilic leukemia, essential thrombocythemia, polycythemia vera

Eligibility Criteria

undefined - 69 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • Diagnosis of advanced hematologic malignancy or other disease not curable by conventional chemotherapy, including any of the following:

    • Acute myeloid leukemia in complete remission (CR)* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria:

      • In first complete remission (CR1) AND has high-risk disease as evidenced by any of the following:

        • Preceding myelodysplastic syndromes (MDS)
        • High-risk cytogenetics (e.g., monosomy 5 or 7, or as defined by referring institution treatment protocol)
        • Required > 2 courses of therapy to obtain CR
        • Erythroblastic or megakaryocytic leukemia
      • In second CR (CR2) or beyond
    • Acute lymphoblastic leukemia in CR* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria:

      • In CR1 AND has high-risk disease as evidenced by any of the following:

        • t(9;22), t(1;19), t(4;11), or other MLL rearrangements
        • Hyplodiploid
        • Required > 1 course of therapy to obtain CR
      • Beyond CR2
    • Chronic myelogenous leukemia (CML)

      • All types are allowed (except refractory blast crisis CML)
      • Patients in chronic phase CML must have failed or been intolerant to prior imatinib mesylate (Gleevec) or other tyrosine kinase inhibitors
    • MDS

      • Any subtype allowed (including refractory anemia [RA])
      • Severe pancytopenia or complex cytogenetics
      • Blasts must be < 5% (if blasts are ≥ 5%, pre-transplant induction therapy is required to reduce blast count to < 5%)
    • Large cell lymphoma, Hodgkin lymphoma, or multiple myeloma, meeting one of the following criteria:

      • Chemotherapy-sensitive disease that has failed prior therapy

        • Patients with large cell lymphoma or Hodgkin lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)
      • Ineligible for an autologous stem cell transplant
    • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, or follicular lymphoma that has progressed after ≥ 2 prior therapies

      • Patients with bulky disease should be considered for debulking chemotherapy prior to transplant
      • Patients with refractory disease are eligible provided disease is non-bulky AND an estimated tumor doubling time is ≥ 1 month
    • Lymphoplasmacytic lymphoma, mantle cell lymphoma, or prolymphocytic leukemia

      • Chemotherapy-sensitive disease that was previously treated with initial therapy

        • Patients with mantle cell lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)
    • Mycosis fungoides and Sezary syndrome
    • Bone marrow failure syndromes, except for Fanconi anemia
    • Myeloproliferative syndromes NOTE: *Patients for whom adequate marrow/biopsy specimens can not be obtained to determine remission status by morphologic assessment must have fulfilled criteria of remission (< 5% blasts by flow cytometry and recovery of peripheral blood counts with no circulating blasts)
  • Ineligible for autologous stem cell transplant due to any of the following:

    • Prior autologous stem cell transplant
    • Inadequate autologous stem cell harvest
    • Inability to withstand a myeloablative preparative regimen
    • Clinically aggressive/high-risk disease
  • No evidence of progressive disease by imaging modalities or biopsy (persistent PET scan activity allowed provided there are no CT scan changes indicating progression)
  • Acute leukemia that is refractory, persistent, or relapsed (defined as > 5% blasts in normocellular bone marrow) allowed provided patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy
  • Patients with stable disease are eligible provided the largest residual nodal mass is approximately < 5 cm (largest residual mass must represent a 50% reduction and be approximately < 7.5 cm for patients who have responded to prior therapy)
  • No active CNS malignancy
  • Umbilical cord blood (UCB) donor available

    • UCB graft matched at 4/6 HLA-A, -B, and -DRB1 antigens with the recipient

      • May include 0-2 antigen mismatches at the A, B, or DRB1 loci
      • Unit selection based on cryopreserved nucleated cell dose and HLA-A, -B, and -DRB1 using intermediate resolution A, B antigen and DRB1 allele typing
    • If 2 UCB units are required to reach the target cell dose, each unit must be a 3/6 HLA-A, -B, and -DRB1 antigen match to each other, as well as a 4/6 antigen match to the recipient
    • No 5-6/6 HLA-A, -B, and -DRB1 matched sibling donor available

PATIENT CHARACTERISTICS:

  • Karnofsky performance status (PS) 60-100% OR Lansky PS 50-100%
  • Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance > 40 mL/min (pediatrics)

    • Adult patients with a creatinine > 1.2 mg/dL or a history of renal dysfunction must have an estimated creatinine clearance of > 40 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • LVEF ≥ 35%
  • DLCO > 30% predicted
  • No requirement for O_2
  • No decompensated congestive heart failure
  • No uncontrolled arrhythmia
  • None of the following liver diseases or conditions:

    • Fulminant liver failure
    • Cirrhosis with evidence of portal hypertension or bridging fibrosis
    • Alcoholic hepatitis
    • Esophageal varices
    • History of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time
    • Ascites related to portal hypertension
    • Bacterial or fungal abscess
    • Biliary obstruction
    • Chronic viral hepatitis with total serum bilirubin > 3 mg/dL
    • Symptomatic biliary disease
  • Recent mold infection (e.g., Aspergillus) allowed provided patient received ≥ 30 days of appropriate treatment AND infection is controlled and cleared by Infectious Disease
  • No evidence of HIV infection or known HIV-positive serology
  • No uncontrolled viral or bacterial infection

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 3 months since prior myeloablative stem cell transplantation

Sites / Locations

  • Fred Hutchinson Cancer Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cyclophosphamide/Fludarabine/TBI

Cyclophosphamide/Fludarabine/TBI/ATG

Arm Description

Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months. Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.

Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months

Outcomes

Primary Outcome Measures

Probability of Survival at 1 Year
Kaplan-Meier estimate of the probability of survival at 1 year

Secondary Outcome Measures

Probability of Survival at 2 Years
Kaplan-Meier estimate of the probability of survival at 2 years
Incidence of Non-relapse Mortality at 6 Months
Number of Participants with Non-relapse Mortality at 6 Months
Chimerism
Count of participants who experienced dominance of one cord blood unit (defined by >or= 95% contribution of one cord blood unit to BM and all PB fractions -- CD3+, CD33+, CD56+, and CD19+) at 7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant.
Incidence of Neutrophil Engraftment at Day 42
Number of participants with neutrophil engraftment at day 42
Incidence of Platelet Engraftment at 6 Months
Number of participants with platelet engraftment at 6 months
Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD) at Day 100
Number of participants with Grade II-IV acute graft-versus-host-disease (GVHD) at day 100. Acute GVHD Staging and Grading: Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)
Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD) at Day 100
Number of participants with Grade III-IV acute graft-versus-host-disease (GVHD) at day 100. Acute GVHD Staging and Grading: Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)
Incidence of Chronic Graft-versus-host-disease (GVHD) at 1 Year
Number of participants with chronic graft-versus-host-disease (GVHD) at 1 year. Clinical Limited cGVHD Oral abnormalities consistent with cGVHD, a positive skin or lip biopsy, and no other manifestations of cGVHD. Mild liver test abnormalities (alkaline phosphatase <2 x upper limit of normal, AST or ALT <3 x upper limit of normal and total bilirubin <1.6) with positive skin or lip biopsy, and no other manifestations of cGVHD. Less than 6 papulosquamous plaques, macular-papular or lichenoid rash involving <20% of body surface area (BSA), dyspigmentation involving <20% BSA, or erythema involving <50% BSA, positive skin biopsy, and no other manifestations of cGVHD. Ocular sicca (Schirmer's test <5mm with no more than minimal ocular symptoms), positive skin or lip biopsy, and no other manifestations of cGVHD. Vaginal or vulvar abnormalities with positive biopsy, and no other manifestations of cGVHD.
Incidence of Clinically Significant Infections at 6 Months
Number of participants with clinically significant infections at 6 months
Incidence of Clinically Significant Infections at 1 Year
Number of participants with clinically significant infections at 1 year
Incidence of Clinically Significant Infections at 2 Years
Number of participants with clinically significant infections at 2 years
Probability of Progression-free Survival at 1 Year
Kaplan-Meier estimate of the probability of progression-free survival at 1 year
Probability of Progression-free Survival at 2 Years
Kaplan-Meier estimate of the probability of progression-free survival at 2 years
Incidence of Relapse at 1 Year
Number of participants with relapse at 1 year. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.
Incidence of Relapse at 2 Years
Number of participants with relapse at 2 years. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.

Full Information

First Posted
July 19, 2008
Last Updated
May 19, 2017
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00719849
Brief Title
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Official Title
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Terminated
Why Stopped
A new protocol was developed to replace this protocol in 2008, with removal of ATG and extension of MMF duration.
Study Start Date
November 2005 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor umbilical cord blood transplant with reduced intensity conditioning works in treating patients with advanced hematological cancer or other disease.
Detailed Description
OBJECTIVES: Primary To estimate the probability of survival at 1 year in patients with advanced hematological malignancies or other diseases treated with non-myeloablative unrelated donor umbilical cord blood transplantation. Secondary Six month non-relapse mortality. Chimerism at days 7, 14, 21, 28, 56, and 80, at 6 months, and at 1 and 2 years. To determine the incidence of neutrophil engraftment at day 42. To determine the incidence of platelet engraftment at 6 months. To determine the incidence of grade II-IV and III-IV acute graft-versus-host-disease (GVHD) at day 100. To determine the incidence of chronic GVHD at 1 year. To determine the incidence of clinically significant infections at 6 months and at 1 and 2 years. To determine the probability of progression-free survival at 1 and 2 years. To determine the probability of survival at 2 years. To determine the incidence of relapse or disease progression at 1 and 2 years. OUTLINE: Patients are stratified according to disease status and prior therapy (hematologic malignancy or other disease that was treated with an autologous stem cell transplant or ≥ 2 courses of multiagent chemotherapy within the past 3 months vs hematologic malignancy or other disease that was treated with an autologous stem cell transplant > 12 months ago or with ≤ 1 course of multiagent chemotherapy or immunosuppressive chemotherapy within the past 3 months vs refractory leukemia or lymphoma for which patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy). Conditioning regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV on day -6. Patients also undergo total body irradiation on day -1. Some patients also receive anti-thymocyte globulin IV on days -6 to -4. Umbilical cord blood transplantation (UCBT): Patients undergo UCBT on day 0. Immunosuppressive therapy (graft-versus-host disease prophylaxis): Patients receive cyclosporine IV over 1 hour or orally (as tolerated) every 8 or 12 hours beginning on day -3 and continuing for approximately 6 months. Patients also receive mycophenolate mofetil IV every 8 hours on days -3 to 5 and then orally on days 6-30. After completion of study treatment, patients are followed at 6 months and then annually thereafter.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Keywords
chronic myelogenous leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, atypical chronic myeloid leukemia, chronic myelomonocytic leukemia, anaplastic large cell lymphoma, splenic marginal zone lymphoma, nodal marginal zone B-cell lymphoma, recurrent adult Hodgkin lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent childhood large cell lymphoma, recurrent mycosis fungoides/Sezary syndrome, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, recurrent/refractory childhood Hodgkin lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, refractory multiple myeloma, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, myelodysplastic/myeloproliferative disease, childhood myelodysplastic syndromes, recurrent childhood anaplastic large cell lymphoma, refractory anemia, refractory anemia with excess blasts, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, stage III adult diffuse large cell lymphoma, stage IV adult diffuse large cell lymphoma, stage III adult immunoblastic large cell lymphoma, stage IV adult immunoblastic large cell lymphoma, stage III childhood anaplastic large cell lymphoma, stage III childhood large cell lymphoma, stage IV childhood anaplastic large cell lymphoma, stage IV childhood large cell lymphoma, stage III adult Hodgkin lymphoma, stage III childhood Hodgkin lymphoma, stage IV adult Hodgkin lymphoma, stage IV childhood Hodgkin lymphoma, stage II multiple myeloma, stage III multiple myeloma, stage III chronic lymphocytic leukemia, stage IV chronic lymphocytic leukemia, stage III small lymphocytic lymphoma, stage IV small lymphocytic lymphoma, stage III marginal zone lymphoma, stage IV marginal zone lymphoma, stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, Waldenstrom macroglobulinemia, stage III mantle cell lymphoma, stage IV mantle cell lymphoma, stage III mycosis fungoides/Sezary syndrome, stage IV mycosis fungoides/Sezary syndrome, juvenile myelomonocytic leukemia, chronic eosinophilic leukemia, chronic idiopathic myelofibrosis, chronic neutrophilic leukemia, essential thrombocythemia, polycythemia vera

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cyclophosphamide/Fludarabine/TBI
Arm Type
Experimental
Arm Description
Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months. Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.
Arm Title
Cyclophosphamide/Fludarabine/TBI/ATG
Arm Type
Experimental
Arm Description
Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
Intervention Type
Biological
Intervention Name(s)
anti-thymocyte globulin
Intervention Description
30mg/Kg Days -6 to -4
Intervention Type
Drug
Intervention Name(s)
cyclophosphamide
Intervention Description
50 mg/Kg Day -6
Intervention Type
Drug
Intervention Name(s)
cyclosporine
Intervention Description
Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
Intervention Type
Drug
Intervention Name(s)
fludarabine phosphate
Intervention Description
40mg/m2 Days -6 to -2
Intervention Type
Drug
Intervention Name(s)
mycophenolate mofetil
Intervention Description
1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
Intervention Type
Procedure
Intervention Name(s)
umbilical cord blood transplantation
Intervention Description
Single or double unit umbilical cord blood transplant
Intervention Type
Radiation
Intervention Name(s)
total body irradiation
Intervention Description
200 cGy Day -1
Primary Outcome Measure Information:
Title
Probability of Survival at 1 Year
Description
Kaplan-Meier estimate of the probability of survival at 1 year
Time Frame
1 year post transplant
Secondary Outcome Measure Information:
Title
Probability of Survival at 2 Years
Description
Kaplan-Meier estimate of the probability of survival at 2 years
Time Frame
2 years post transplant
Title
Incidence of Non-relapse Mortality at 6 Months
Description
Number of Participants with Non-relapse Mortality at 6 Months
Time Frame
6 months post transplant
Title
Chimerism
Description
Count of participants who experienced dominance of one cord blood unit (defined by >or= 95% contribution of one cord blood unit to BM and all PB fractions -- CD3+, CD33+, CD56+, and CD19+) at 7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant.
Time Frame
7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant
Title
Incidence of Neutrophil Engraftment at Day 42
Description
Number of participants with neutrophil engraftment at day 42
Time Frame
Day 42 post transplant
Title
Incidence of Platelet Engraftment at 6 Months
Description
Number of participants with platelet engraftment at 6 months
Time Frame
6 months post transplant
Title
Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD) at Day 100
Description
Number of participants with Grade II-IV acute graft-versus-host-disease (GVHD) at day 100. Acute GVHD Staging and Grading: Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)
Time Frame
Day 100 post transplant
Title
Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD) at Day 100
Description
Number of participants with Grade III-IV acute graft-versus-host-disease (GVHD) at day 100. Acute GVHD Staging and Grading: Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)
Time Frame
Day 100 post transplant
Title
Incidence of Chronic Graft-versus-host-disease (GVHD) at 1 Year
Description
Number of participants with chronic graft-versus-host-disease (GVHD) at 1 year. Clinical Limited cGVHD Oral abnormalities consistent with cGVHD, a positive skin or lip biopsy, and no other manifestations of cGVHD. Mild liver test abnormalities (alkaline phosphatase <2 x upper limit of normal, AST or ALT <3 x upper limit of normal and total bilirubin <1.6) with positive skin or lip biopsy, and no other manifestations of cGVHD. Less than 6 papulosquamous plaques, macular-papular or lichenoid rash involving <20% of body surface area (BSA), dyspigmentation involving <20% BSA, or erythema involving <50% BSA, positive skin biopsy, and no other manifestations of cGVHD. Ocular sicca (Schirmer's test <5mm with no more than minimal ocular symptoms), positive skin or lip biopsy, and no other manifestations of cGVHD. Vaginal or vulvar abnormalities with positive biopsy, and no other manifestations of cGVHD.
Time Frame
1 year post transplant
Title
Incidence of Clinically Significant Infections at 6 Months
Description
Number of participants with clinically significant infections at 6 months
Time Frame
6 months post transplant
Title
Incidence of Clinically Significant Infections at 1 Year
Description
Number of participants with clinically significant infections at 1 year
Time Frame
1 year post transplant
Title
Incidence of Clinically Significant Infections at 2 Years
Description
Number of participants with clinically significant infections at 2 years
Time Frame
2 years post transplant
Title
Probability of Progression-free Survival at 1 Year
Description
Kaplan-Meier estimate of the probability of progression-free survival at 1 year
Time Frame
1 year post transplant
Title
Probability of Progression-free Survival at 2 Years
Description
Kaplan-Meier estimate of the probability of progression-free survival at 2 years
Time Frame
2 years post transplant
Title
Incidence of Relapse at 1 Year
Description
Number of participants with relapse at 1 year. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.
Time Frame
1 year post transplant
Title
Incidence of Relapse at 2 Years
Description
Number of participants with relapse at 2 years. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.
Time Frame
2 years post transplant

10. Eligibility

Sex
All
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of advanced hematologic malignancy or other disease not curable by conventional chemotherapy, including any of the following: Acute myeloid leukemia in complete remission (CR)* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria: In first complete remission (CR1) AND has high-risk disease as evidenced by any of the following: Preceding myelodysplastic syndromes (MDS) High-risk cytogenetics (e.g., monosomy 5 or 7, or as defined by referring institution treatment protocol) Required > 2 courses of therapy to obtain CR Erythroblastic or megakaryocytic leukemia In second CR (CR2) or beyond Acute lymphoblastic leukemia in CR* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria: In CR1 AND has high-risk disease as evidenced by any of the following: t(9;22), t(1;19), t(4;11), or other MLL rearrangements Hyplodiploid Required > 1 course of therapy to obtain CR Beyond CR2 Chronic myelogenous leukemia (CML) All types are allowed (except refractory blast crisis CML) Patients in chronic phase CML must have failed or been intolerant to prior imatinib mesylate (Gleevec) or other tyrosine kinase inhibitors MDS Any subtype allowed (including refractory anemia [RA]) Severe pancytopenia or complex cytogenetics Blasts must be < 5% (if blasts are ≥ 5%, pre-transplant induction therapy is required to reduce blast count to < 5%) Large cell lymphoma, Hodgkin lymphoma, or multiple myeloma, meeting one of the following criteria: Chemotherapy-sensitive disease that has failed prior therapy Patients with large cell lymphoma or Hodgkin lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky) Ineligible for an autologous stem cell transplant Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, or follicular lymphoma that has progressed after ≥ 2 prior therapies Patients with bulky disease should be considered for debulking chemotherapy prior to transplant Patients with refractory disease are eligible provided disease is non-bulky AND an estimated tumor doubling time is ≥ 1 month Lymphoplasmacytic lymphoma, mantle cell lymphoma, or prolymphocytic leukemia Chemotherapy-sensitive disease that was previously treated with initial therapy Patients with mantle cell lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky) Mycosis fungoides and Sezary syndrome Bone marrow failure syndromes, except for Fanconi anemia Myeloproliferative syndromes NOTE: *Patients for whom adequate marrow/biopsy specimens can not be obtained to determine remission status by morphologic assessment must have fulfilled criteria of remission (< 5% blasts by flow cytometry and recovery of peripheral blood counts with no circulating blasts) Ineligible for autologous stem cell transplant due to any of the following: Prior autologous stem cell transplant Inadequate autologous stem cell harvest Inability to withstand a myeloablative preparative regimen Clinically aggressive/high-risk disease No evidence of progressive disease by imaging modalities or biopsy (persistent PET scan activity allowed provided there are no CT scan changes indicating progression) Acute leukemia that is refractory, persistent, or relapsed (defined as > 5% blasts in normocellular bone marrow) allowed provided patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy Patients with stable disease are eligible provided the largest residual nodal mass is approximately < 5 cm (largest residual mass must represent a 50% reduction and be approximately < 7.5 cm for patients who have responded to prior therapy) No active CNS malignancy Umbilical cord blood (UCB) donor available UCB graft matched at 4/6 HLA-A, -B, and -DRB1 antigens with the recipient May include 0-2 antigen mismatches at the A, B, or DRB1 loci Unit selection based on cryopreserved nucleated cell dose and HLA-A, -B, and -DRB1 using intermediate resolution A, B antigen and DRB1 allele typing If 2 UCB units are required to reach the target cell dose, each unit must be a 3/6 HLA-A, -B, and -DRB1 antigen match to each other, as well as a 4/6 antigen match to the recipient No 5-6/6 HLA-A, -B, and -DRB1 matched sibling donor available PATIENT CHARACTERISTICS: Karnofsky performance status (PS) 60-100% OR Lansky PS 50-100% Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance > 40 mL/min (pediatrics) Adult patients with a creatinine > 1.2 mg/dL or a history of renal dysfunction must have an estimated creatinine clearance of > 40 mL/min Not pregnant or nursing Negative pregnancy test LVEF ≥ 35% DLCO > 30% predicted No requirement for O_2 No decompensated congestive heart failure No uncontrolled arrhythmia None of the following liver diseases or conditions: Fulminant liver failure Cirrhosis with evidence of portal hypertension or bridging fibrosis Alcoholic hepatitis Esophageal varices History of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time Ascites related to portal hypertension Bacterial or fungal abscess Biliary obstruction Chronic viral hepatitis with total serum bilirubin > 3 mg/dL Symptomatic biliary disease Recent mold infection (e.g., Aspergillus) allowed provided patient received ≥ 30 days of appropriate treatment AND infection is controlled and cleared by Infectious Disease No evidence of HIV infection or known HIV-positive serology No uncontrolled viral or bacterial infection PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 3 months since prior myeloablative stem cell transplantation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Colleen Delaney, MD, MSC
Organizational Affiliation
Fred Hutchinson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fred Hutchinson Cancer Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

We'll reach out to this number within 24 hrs